Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21295696 | 0.77 | PIN1 (0.41) | GPR84PIN1PTPN1 | |
| SCHEMBL547208 | 0.73 | PTPN1 (0.36) | PTPN1 | |
| SCHEMBL28274316 | 0.70 | PTPN1 (0.37) | HTR1BPTPN1 | |
| SCHEMBL21297634 | 0.70 | GSK3B (0.37) | — | |
| SCHEMBL21295661 | 0.70 | PSMD14 (0.44) | GPR84 | |
| SCHEMBL29756248 | 0.69 | DYRK1A (0.50) | HTR1B | |
| SCHEMBL18574533 | 0.69 | PIN1 (0.41) | PIN1HTR1BMIF | |
| SCHEMBL30646399 | 0.66 | DYRK1A (0.48) | PTPN1 | |
| SCHEMBL891207 | 0.66 | DYRK1A (0.48) | PTPN1 | |
| SCHEMBL9126332 | 0.66 | ALDH1A1 (0.47) | MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176840-A1 | USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | KONKEL MICHAEL | 2009-07-09 | — | — | US | claimed |
| US-8357706-B2 | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | RECEPTOS, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20110178056-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178056-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | S1PR1, S1PR3, S1PR2 | GPR84 98/4885PIN1 1534/4885HTR1B 385/4885 |
| US-20090176840-A1 | USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | GALR3, GALR1, GALR2 | GPR84 159/4885PIN1 2554/4885HTR1B 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.